retatrutide clinical trials news CT Health | Doctors are warning patients against using unapproved versions of retatrutide, an experimental Eli Lilly weight loss drug still in Eli Lilly says next-generation weight

Many drugs going to the cemetery and being taken off the market, causing side effects and cardiovascular problems that caused them either not to be used or to be taken off the market

In conclusion, the findings of our study, comprising a combined cohort of over 38 million individuals with T2DM and controls, suggest that the use of GLP-1 RAs is not associated with an increased risk of cancers, including pancreatic cancer and MTC, compared with the use of other antidiabetic drugs

56-OR: A long-acting glucose-dependent insulinotropic polypeptide receptor agonist shows weight loss without nausea or vomiting

Its about using real science to address the why behind weight struggles, and pairing that with a plan tailored just for you